Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., Bowyer, S., de Miguel, M., Han, S.-W., Krebs, M. G., Lee, J.-S., Cheng, M. L., Arbour, K., Massarelli, E., Choi, Y., ... Freres, P. (Other coll.). (24 August 2023). Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. New England Journal of Medicine, 389 (8), 710 - 721. doi:10.1056/NEJMoa2303810 |
Lambert, N., El Moussaoui, M., & FRERES, P. (10 November 2021). Prise en charge multidisciplinaire de la leucoencéphalopathie multifocale progressive [Paper presentation]. Grandes cliniques intégrées du CHU de Liège. |
ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., ... Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571 |
Uyisenga, J. P.* , Debit, A.* , Poulet, C., Frères, P., Poncin, A., Thiry, J., Mutesa, L., Jerusalem, G., Bours, V.* , & JOSSE, C.*. (03 June 2021). Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites. Scientific Reports, 11 (1), 11698. doi:10.1038/s41598-021-91278-0 * These authors have contributed equally to this work. |
Debruche, M., Mettlen, C., PAULUS, A., VAILLANT, F., Sibille, A., Freres, P., Duysinx, B., & Louis, R. (May 2021). Cancer pulmonaire non à petites cellules chez les patients non fumeurs au CHU de Liège : étude rétrospective entre début 2017 et fin 2018. Revue Médicale de Liège, 76 (5-6), 446 - 451. |
Freres, P., Poncin, A., & Lecocq, M. (May 2021). Les manifestations indésirables liées à l’immunothérapie. Revue Médicale de Liège, 76 (5-6), 403 - 407. |
Martin, D., Bianchi, E., Ben Mustapha, S., & Freres, P. (May 2021). Le glioblastome. Revue Médicale de Liège, 76 (5-6), 419 - 424. |
Denis, C., Sakalihasan, S., FRERES, P., WITHOFS, N., & SAUTOIS, B. (2021). Cemiplimab for cisplatin resistant metastatic penile cancer. Case Reports in Oncology, 14, 972-976. doi:10.1159/000517008 |
LECOCQ, M., ONESTI, C. E., SCHROEDER, H., RORIVE, A., Goffin, M., GONNE, E., SAUTOIS, B., Catot, A., WERA, O., NICOLAERS, L., COLLINGE, A., Collignon, J., FRERES, P., POLUS, M., DUYSINX, B., VAILLANT, F., GENNIGENS, C., MARCHAL, N., PONCIN, A., & JERUSALEM, G. (2020). Risk of SARS-CoV-2 infection and outcome after infection : Experience from the day-care unit at CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
ONESTI, C. E., SCHROEDER, H., RORIVE, A., SAUTOIS, B., LECOCQ, M., Goffin, M., GONNE, E., COLLINGE, A., NICOLAERS, L., WERA, O., Catot, A., LOLY, C., PAULUS, A., SIBILLE, A., LOUSBERG, L., Troisfontaine, F., COLLIGNON, J., GENNIGENS, C., FRERES, P., & JERUSALEM, G. (2020). How do oncological patients perceive the Covid-19 (SARS-CoV-2) pandemic ? Experience from CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
ONESTI, C. E., FRERES, P., & JERUSALEM, G. (2019). Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment. Journal of Thoracic Disease. doi:10.21037/jtd.2018.12.47 |
ONESTI, C. E., JOSSE, C., Poncin, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (2018). Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget. doi:10.18632/oncotarget.26120 |
ONESTI, C. E., JOSSE, C., PONCIN, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (13 September 2018). Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment [Paper presentation]. GIGA-Cancer Day 2018 / EDT-Cancerology Vascular landscape and (pre)metastatic niche in cancer biology. |
FRERES, P. (2018). Les rôles des micro-ARN circulants dans le cancer du sein [Doctoral thesis, Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/315030 |
Freres, P., Bouznad, N., Servais, L., JOSSE, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 18 (1). doi:10.1186/s12885-018-4015-4 |
FRERES, P., GENNIGENS, C., Martin, D., & Jerusalem, G. (October 2017). Leptomeningeal carcinomatosis from solid tumours : a systematic review of the literature. Belgian Journal of Medical Oncology, 11, 259-264. |
Wenric, S., El Guendi, S., CABERG, J.-H., Bezzaou, W., Fasquelle, C., Charloteaux, B., Karim, L., Hennuy, B., FRERES, P., COLLIGNON, J., BOUKERROUCHA, M., SCHROEDER, H., Olivier, F., Jossa, V., JERUSALEM, G., JOSSE, C., & BOURS, V. (May 2017). Transcriptome wide analysis of natural antisense transcripts shows potential role in breast cancer [Poster presentation]. 50th meeting of the European Society of Human Genetics, Copenhagen, Denmark. |
Wenric, S., ElGuendi, S., CABERG, J.-H., Bezzaou, W., Fasquelle, C., Charloteaux, B., Karim, L., Hennuy, B., FRERES, P., COLLIGNON, J., BOUKERROUCHA, M., SCHROEDER, H., OLIVIER, F., Jossa, V., Jerusalem, G., JOSSE, C., & Bours, V. (2017). Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer. Scientific Reports, 7 (1), 17452. doi:10.1038/s41598-017-17811-2 |
FRERES, P., LOUSBERG, L., & JERUSALEM, G. (July 2016). Cyclin-dependent protein kinase inhibitors in breast cancer treatment. Belgian Journal of Medical Oncology, 10 (4), 132-138. |
FRERES, P., PONCIN, A., MOONEN, M., Josse, C., Oury, C., BOURS, V., LANCELLOTTI, P., & JERUSALEM, G. (2016). La cardiotoxicité des traitements anti-cancéreux. Revue Médicale de Liège, 71 (9), 382-387. |
Freres, P.* , Wenric, S.* , BOUKERROUCHA, M., Fasquelle, C., Thiry, J., Bovy, N., Struman, I., Geurts, P., COLLIGNON, J., SCHROEDER, H., KRIDELKA, F., LIFRANGE, E., Jossa, V., Bours, V.* , Josse, C.* , & JERUSALEM, G.*. (2015). Circulating microRNA-based screening tool for breast cancer. Oncotarget. doi:10.18632/oncotarget.6786 * These authors have contributed equally to this work. |
Boukerroucha, M., Josse, C., SEGERS, K., El Guendi, S., FRERES, P., JERUSALEM, G., & Bours, V. (26 March 2015). BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer, 15, 181. doi:10.1186/s12885-015-1205-1 |
Boukerroucha, M., Josse, C., El Guendi, S., FRERES, P., Marée, R., Wenric, S., SEGERS, K., COLLIGNON, J., JERUSALEM, G., & BOURS, V. (2015). Genetic study of triple negative breast cancers [Poster presentation]. Impakt Breast Cancer Conference, Brussels, Belgium. doi:10.1093/annonc/mdv116.11 |
Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J., Noël, A., Thiry, M., Jerusalem, G., Josse, C., Bours, V., Tabruyn, S., & Struman, I. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. doi:10.18632/oncotarget.3520 |
FRERES, P., GONNE, E., COLLIGNON, J., GIOT, J.-B., GENNIGENS, C., & JERUSALEM, G. (2015). Prise en charge de la neutropénie fébrile chez le patient cancéreux. Revue Médicale de Liège, 70 (4), 195-200. |
JERUSALEM, G., COLLIGNON, J., Josse, C., SCHROEDER, H., RORIVE, A., FRERES, P., LAMBERT, F., KOOPMANSCH, B., PONCIN, A., & BOURS, V. (2015). Cancer du sein : de la thérapie ciblée à la médecine personnalisée. Revue Médicale de Liège, 70 (5-6), 269-276. |
JERUSALEM, G., MOONEN, M., FRERES, P., & LANCELLOTTI, P. (2015). The European Association of Cardiovascular Imaging/Heart Faiture Association Cardiac Oncology Toxicity Registry : long-term benefits for breast cancer treatment. Future Oncology, 11 (20), 2791-2794. doi:10.2217/fon.15.227 |
FRERES, P., JOSSE, C., Bovy, N., Boukerroucha, M., Struman, I., BOURS, V., & JERUSALEM, G. (2014). Neoadjuvant chemotherapy in breast cancer induces miR-34a and miR-122 expression. Journal of Cellular Physiology. doi:10.1002/jcp.24730 |
FRERES, P. (19 May 2014). Neoadjuvant chemotherapy in breast cancer patients induces expression of tumor suppressor miR-34a [Poster presentation]. GIGA Cancer Day, Liège, Belgium. |
FRERES, P. (24 April 2014). Circulating microRNAs as diagnostic markers in breast cancer patients and their deregulation under neoadjuvant chemotherapy [Poster presentation]. Belgian Medical Genomics Initiative Annual Meeting 2014, Liège, Belgium. |
Wenric, S., Freres, P., Josse, C., Bours, V., & Jerusalem, G. (09 December 2013). A miRNA expression based diagnostic tool for breast cancer using random forests [Poster presentation]. Benelux Bioinformatics Conference 2013. |
FRANCHIMONT, D., Freres, P., LEBRUN, F., FASSOTTE, M.-F., & D'Orio, V. (1996). Le cas clinique du mois : syndrome de Moskowitz chez un patient traité par ticlopidine. Revue Médicale de Liège, 51 (3), 214-216. |